Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
